Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

AbbVie Inc. (ABBV) — XLV Health Care · S&P 500 Profile |艾伯維公司介紹

health-careS&P500SPX Top25xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

AbbVie Inc. (ABBV) — Business, History & S&P 500 Profile |艾伯維公司介紹

AbbVie company profile · business segments · history · financial snapshot · S&P 500 rank #20 · 艾伯維公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data: assignment baselines
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$504B
Oct 16, 2026 · #3 in Health Care
S&P 500 WEIGHT
0.71%
Rank #20 · Oct 21, 2026 (Slickcharts)
FY2025 NET REVENUES
$61.16B
+8.6% YoY · record revenue year
FY2025 NET EARNINGS
$4.23B
Net margin 6.9% · Adj. diluted EPS $10.00

SNAPSHOT

TickerABBV (NYSE)
CompanyAbbVie Inc.
GICS sector / industryHealth Care (XLV) / Biotechnology
S&P 500 rank (by weight)#20 · 0.71% (Oct 21, 2026)
Sector rank (by market cap)#3 in Health Care (Oct 16, 2026)
HeadquartersNorth Chicago, Illinois (1 North Waukegan Road)
FoundedJanuary 1, 2013 (spin-off from Abbott Laboratories; incorporated in Delaware April 10, 2012)
CEORobert A. Michael (chairman & CEO; CEO since July 1, 2024, chairman since July 1, 2025)
Employees~57,000 in over 70 countries (Dec 31, 2025, FY2025 10-K)
Market cap$504B (assignment baseline)
SEC filingsEDGAR — CIK 0001551152

WHAT IT DOES

AbbVie Inc. is a global biopharmaceutical company headquartered in North Chicago, Illinois — in the company's own words, "the discovery, development, manufacturing and sale of a broad line of therapies that address some of the world's most complex and serious diseases" (FY2025 10-K). Its one-line model: develop or acquire patent-protected branded medicines, then sell them worldwide through wholesalers, distributors, government agencies and specialty pharmacies — and, for aesthetics, directly to physicians and other licensed providers. Immunology is the engine: nearly half of FY2025's record $61.160B of net revenues came from the immunology portfolio.

AbbVie reports as a single global business segment; management discusses revenue by therapeutic portfolio. Immunology ($30.406B, +14.0%) is Skyrizi ($17.562B, +49.9%) and Rinvoq ($8.304B, +39.1%) — the two drugs replacing Humira ($4.540B, −49.5%) as it falls off the industry's largest patent cliff. Neuroscience ($10.767B, +19.6%) is the fastest-growing therapeutic area: Vraylar ($3.621B), Botox Therapeutic ($3.769B), Ubrelvy ($1.271B), Qulipta ($1.036B) and Vyalev ($482M, up from $99M in 2024). Oncology ($6.655B, +1.5%) is Venclexta ($2.792B, +8.1%) offsetting Imbruvica's decline ($2.869B, −14.3%), plus the Elahere antibody-drug conjugate ($690M, +44.0%). Aesthetics ($4.860B, −6.1%) is Botox Cosmetic ($2.602B) and the Juvederm Collection ($993M, −15.6%), under consumer pressure. Eye Care ($2.109B, −5.9%) and Other Key Products ($3.736B, +2.4% — Creon $1.512B, Mavyret $1.317B, Linzess $907M) round out the mix.

The business model is a patent-cliff treadmill run at scale: GAAP R&D of $9.096B plus adjusted R&D investment of $13.8B in 2025, and more than $5B of 2025 business development (a novel psychedelic compound for major depressive disorder, in-vivo CAR-T, an siRNA platform and an amylin analog for obesity) to rebuild the pipeline as Humira fades. The 2020 Allergan acquisition diversified the revenue base into aesthetics and eye care, and the Immunogen, Cerevel, Aliada and Capstan deals (with the $10.9B Apogee acquisition announced in June 2026) keep the oncology and neuroscience pipelines fed. Strong cash generation — $19.030B of operating cash flow in 2025 — funds one of health care's longest dividend streaks ($11.657B paid out in 2025).

BUSINESS SEGMENTS — FY2025 NET REVENUES BY THERAPEUTIC PORTFOLIO

PortfolioNet revenueShareYoYKey products
Immunology$30.406B49.7%+14.0%Skyrizi $17.56B · Rinvoq $8.30B · Humira $4.54B
Neuroscience$10.767B17.6%+19.6%Vraylar $3.62B · Botox Therapeutic $3.77B · Ubrelvy $1.27B · Qulipta $1.04B
Oncology$6.655B10.9%+1.5%Venclexta $2.79B · Imbruvica $2.87B · Elahere $0.69B · Epkinly $0.27B
Aesthetics$4.860B7.9%−6.1%Botox Cosmetic $2.60B · Juvederm Collection $0.99B
Other key products$3.736B6.1%+2.4%Creon $1.51B · Mavyret $1.32B · Linzess $0.91B
Eye care$2.109B3.4%−5.9%Ozurdex $0.49B · Lumigan/Ganfort $0.41B
All other$2.627B4.3%n/m—
Total net revenues$61.160B100%+8.6%—
Source: AbbVie FY2025 Form 10-K (year ended Dec 31, 2025), key product revenues. AbbVie reports as a single global business segment (innovative medicines and therapies); the portfolios above are the therapeutic basis on which management discusses the business. Shares are computed as portfolio revenue ÷ $61.160B and may not sum to 100% due to rounding. YoY is reported-basis.

Immunology is the post-Humira growth engine. Skyrizi and Rinvoq combined for $25.866B in 2025 — up $8.2B year over year — while Humira fell from $14.404B in 2023 to $4.540B; CEO Robert Michael noted "close to $16B in U.S. Humira erosion since" loss of exclusivity, and management targets more than $31B of combined Skyrizi/Rinvoq sales by 2027.

Neuroscience is the fastest-growing therapeutic area (+19.6%), anchored by Vraylar and Botox Therapeutic and extended by the migraine pair Ubrelvy/Qulipta ($2.307B combined) and the Parkinson's launch Vyalev. The 2024 Cerevel acquisition ($8.7B) deepened the neuroscience pipeline; management expects the Parkinson's franchise (Vyalev plus tavapadon) to exceed $5B in peak sales.

Oncology is in transition: Venclexta (+8.1%) and the Elahere antibody-drug conjugate (+44.0%) are growing while Imbruvica (−14.3%) faces IRA Medicare price pressure and next-generation BTK competition. The 2024 ImmunoGen acquisition ($10.1B) brought Elahere into the fold.

Aesthetics and Eye Care are the Allergan legacy — cash-generative but cyclical (aesthetics −6.1% on consumer softness) and exposed to generics (eye care −5.9%, led by Restasis pressure).

HISTORY

YearMilestone
2012April 10 — AbbVie Inc. incorporated in Delaware (FY2025 10-K, Note 1)
2013January 1 — Spin-off from Abbott Laboratories completed; AbbVie becomes an independent publicly-traded company, inheriting Humira (FY2025 10-K, Note 1)
2015Acquires Pharmacyclics for $21B — bringing Imbruvica, AbbVie's first big oncology blockbuster (company IR)
2019–20Allergan acquisition announced (June 2019) and closed May 8, 2020 for $63B — adding Botox, the Juvederm Collection and the eye-care franchise (company IR)
2023First U.S. biosimilar competition for Humira (January) — "the pharmaceutical industry's largest patent cliff in history" (10-K shareholder letter); Humira U.S. sales begin their steep erosion
2024ImmunoGen acquisition closed (February, $10.1B) — Elahere antibody-drug conjugate franchise; Cerevel Therapeutics acquisition closed (August, $8.7B) — neuroscience pipeline; Aliada Therapeutics acquired (December, $1.4B) — Alzheimer's antibody
2024July 1 — Robert A. Michael becomes chief executive officer; Vyalev approved by the FDA for advanced Parkinson's disease (October)
2025Key approvals: Rinvoq for giant cell arteritis, Emrelis (telisotuzumab vedotin) for non-squamous non-small cell lung cancer, Epkinly for second-line follicular lymphoma (10-K shareholder letter); Capstan Therapeutics acquired ($2.1B) — in-vivo CAR-T platform; $906M upfront for Gilgamesh's psychedelic MDD compound
2025July 1 — Michael becomes chairman of the board; Rick Gonzalez retires as executive chairman (10-K lead-director letter)
2026June 22 (announcement) — Definitive agreement to acquire Apogee Therapeutics for $10.9B in equity value, deepening the immunology portfolio (long-acting biologics); expected to close in Q3 2026 (Q2 2026 earnings release)

COMPETITIVE POSITION

  • Scale — ~$504B market cap, the #3 Health Care constituent by market cap and S&P 500 #20 at a 0.71% weight; FY2025 net revenues of $61.160B were a company record.
  • Immunology engine — Skyrizi ($17.562B, +49.9%) and Rinvoq ($8.304B, +39.1%) combined for $25.866B in 2025, 42.3% of total revenue and up $8.2B year over year; management targets more than $31B combined by 2027 (Q4 2025 call).
  • Fastest-growing therapeutic area — Neuroscience revenue of $10.767B grew 19.6% in 2025, led by Vraylar and Botox Therapeutic; the Parkinson's franchise (Vyalev plus tavapadon) is expected to exceed $5B in peak sales.
  • Allergan diversification — Aesthetics ($4.860B) and eye care ($2.109B) give AbbVie cash-generating franchises outside traditional pharma cycles, though both declined in 2025.
  • Dividend machine — 54 consecutive annual dividend increases (Oct 2026); $11.657B of dividends paid in 2025 against $17.8B of free cash flow; quarterly dividend raised 5.5% to $1.73 (Oct 31, 2025, payable Feb 17, 2026).
  • R&D and BD firepower — GAAP R&D $9.096B plus adjusted R&D investment of $13.8B in 2025; more than $5B of 2025 business development (Gilgamesh psychedelic compound, in-vivo CAR-T, siRNA platform, amylin analog for obesity); the pending $10.9B Apogee deal extends immunology into long-acting biologics.
  • Competition set — Johnson & Johnson, Eli Lilly, Novartis and Amgen in immunology and biosimilars; Galderma and Merz in aesthetics; Genmab (Epkinly partner) in bispecific oncology; IRA Medicare price negotiation is already hitting Imbruvica.

FINANCIAL SNAPSHOT — FY2025

Total net revenues$61.160B (+8.6% reported / +8.5% operational YoY; FY2024 $56.334B)
Cost of products sold$18.204B (+7.7% YoY)
Gross profit / gross margin$42.956B / 70.2% (computed from reported figures)
SG&A$14.010B (−5.0% YoY)
R&D (GAAP)$9.096B (−28.9% YoY; FY2024 included large Cerevel/ImmunoGen charges)
Acquired IPR&D and milestones$5.016B
Operating earnings / operating margin$15.075B / 24.6% (computed from reported figures)
Adjusted R&D investment (non-GAAP)$13.8B (10-K shareholder letter)
Net earnings$4.233B (attributable to AbbVie $4.226B); net margin 6.9% (computed)
Diluted EPS (GAAP)$2.36 (vs $2.39 in FY2024)
Adjusted diluted EPS (non-GAAP)$10.00 (−1.2% YoY; incl. −$2.76/share of acquired IPR&D and milestones)
Operating cash flow$19.030B
Capital expenditures$1.214B
Free cash flow$17.816B (operating cash flow − capex; computed)
Total debt$64.997B (long-term debt & finance lease obligations, Dec 31, 2025)
Cash and equivalents$5.229B (Dec 31, 2025)
Net debt$59.768B (total debt − cash; computed)
Dividends paid$11.657B; quarterly dividend raised 5.5% to $1.73 (Oct 31, 2025; payable Feb 17, 2026; annualized $6.92)
Latest quarter (Q2 2026, ended Jun 30, 2026)Net revenues $16.990B (+10.2% YoY) · GAAP diluted EPS $2.03 (+290.4%) · Adjusted diluted EPS $3.65 (+22.9%; incl. −$0.17/share IPR&D) · Adjusted gross margin 84.7% · Adjusted operating margin 48.3% · FY2026 guidance: net revenues ~$67.6B, adjusted diluted EPS $13.87–14.07 (incl. $0.14 of Apogee dilution)
Source: AbbVie FY2025 Form 10-K (filed Feb 2026) and Q2 2026 earnings release (July 31, 2026). The gap between operating earnings ($15.075B) and net earnings ($4.233B) is $10.842B: $2.627B of net interest expense + $0.058B net foreign-exchange loss + $5.793B of other expense + $2.364B of income tax (FY2025 10-K). Margins and free cash flow are computed from reported figures: gross margin ($61.160B − $18.204B) ÷ $61.160B = 70.2%; operating margin $15.075B ÷ $61.160B = 24.6%; net margin $4.233B ÷ $61.160B = 6.9%; free cash flow $19.030B − $1.214B = $17.816B; net debt $64.997B − $5.229B = $59.768B.

KEY RISKS

  • Concentration — Skyrizi and Rinvoq together are 42.3% of revenue (immunology is 49.7%); a safety signal, reimbursement setback or competitive loss for either is a company-level event.
  • Humira's long tail — still eroding (−49.5% to $4.540B in 2025) as biosimilar competition and exclusive biosimilar contracting spread; further access declines are expected.
  • Imbruvica pressure — IRA Medicare price negotiation plus next-generation BTK competition drove a 14.3% revenue decline in FY2025 and 29.4% in Q2 2026.
  • Leverage — net debt of $59.8B at Dec 31, 2025 (total debt $65.0B); the $10.9B Apogee acquisition adds debt, and management's commitment to return to ~2x net leverage within 2–3 years of closing constrains buybacks and BD flexibility.
  • Pipeline and BD dependence — $5.016B of acquired IPR&D and milestones in 2025 plus $6.495B of contingent-consideration fair-value change keep GAAP earnings noisy and make growth dependent on acquired science.
  • Pricing and cycles — U.S. payer and IRA pricing pressure across the portfolio; aesthetics (−6.1% in 2025) is exposed to consumer discretionary cycles.

WHY IT MATTERS FOR THE S&P 500

AbbVie is the index's #20 constituent at a 0.71% weight — a 1% move in ABBV moves the S&P 500 by roughly 0.7 basis points — and the #3 Health Care name by market cap. It is the index's purest large-cap biotech bellwether (GICS sub-industry Biotechnology), sitting alongside Johnson & Johnson, Eli Lilly and UnitedHealth as one of the sector's anchor weights in XLV.

For market-structure watchers, ABBV is the sector's read-through on three themes: the pace of biosimilar erosion after the industry's largest patent cliff (Humira), the pricing power of next-generation immunology biologics (Skyrizi/Rinvoq), and the real-world impact of IRA Medicare drug-price negotiation (Imbruvica). With 54 consecutive annual dividend increases, it is also the income anchor of Health Care — its $11.657B of 2025 dividends were comfortably covered by $17.8B of free cash flow.

SOURCES & METHODOLOGY

Financials, segments, employees, debtAbbVie FY2025 Form 10-K (filed Feb 2026; year ended Dec 31, 2025; consolidated statements, Note 1, segment disclosure)
Latest quarter (Q2 2026)AbbVie Q2 2026 earnings release (July 31, 2026; quarter ended Jun 30, 2026)
Index weight & rankAssignment baselines (SPX #20 · 0.71%)
Market cap & sector rankAssignment baselines ($504B · #3 in Health Care)
History10-K Note 1 (incorporation, Abbott spin-off); 10-K shareholder and lead-director letters (leadership, Humira LOE, 2025 BD & approvals); AbbVie IR press releases (Pharmacyclics, Allergan, ImmunoGen, Cerevel, Aliada, Capstan, Apogee)
DividendAbbVie IR (Oct 31, 2025 dividend declaration); dividend history (stockanalysis.com, Oct 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.

Price Chart — 10-Year Monthly Candles

AbbVie

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號ABBV(NYSE)
公司AbbVie Inc.(艾伯維)
GICS 板塊/行業醫療健康(XLV)/生物科技
標普500排名(按權重)#20 · 0.71%(任務基線)
板塊內排名(按市值)醫療健康 #3(任務基線)
總部伊利諾州北芝加哥(1 North Waukegan Road)
成立2013年1月1日(自 Abbott Laboratories 分拆;2012年4月10日於德拉瓦州註冊成立)
執行長Robert A. Michael(董事長兼執行長;2024年7月1日出任執行長,2025年7月1日出任董事長)
員工約57,000人,遍佈70多個國家(2025年12月31日,FY2025 10-K)
市值$504B(5,040億美元)(任務基線)
SEC 申報EDGAR — CIK 0001551152

業務概覽

艾伯維是一家總部位於伊利諾州北芝加哥的全球生物製藥公司——用公司自己的話說,從事「針對全球最複雜、最嚴重疾病的廣泛療法的發現、開發、製造與銷售」(FY2025 10-K)。一句話商業模式:開發或收購有專利保護的品牌藥,再透過批發商、經銷商、政府機構與專科藥房銷往全球;醫美產品則直接銷售給醫師等執業醫療提供者。免疫學是引擎:FY2025 創紀錄的 $61.160B(611.6億美元)淨營收中,近一半來自免疫學產品組合。

艾伯維按單一全球業務板塊申報;管理層按治療領域討論營收。免疫學($30.406B(304.06億美元),同比 +14.0%)靠 Skyrizi($17.562B(175.62億美元),+49.9%)與 Rinvoq($8.304B(83.04億美元),+39.1%)接替 Humira($4.540B(45.4億美元),−49.5%)走下製藥史上最大專利懸崖。神經科學($10.767B(107.67億美元),+19.6%)是增長最快的治療領域:Vraylar($3.621B(36.21億美元))、Botox Therapeutic($3.769B(37.69億美元))、Ubrelvy($1.271B(12.71億美元))、Qulipta($1.036B(10.36億美元))與 Vyalev($482M(4.82億美元),2024年為 $99M(9,900萬美元))。腫瘤學($6.655B(66.55億美元),+1.5%)靠 Venclexta($2.792B(27.92億美元),+8.1%)抵銷 Imbruvica 的下滑($2.869B(28.69億美元),−14.3%),加上抗體藥物複合體 Elahere($690M(6.9億美元),+44.0%)。醫美($4.860B(48.6億美元),−6.1%)是 Botox Cosmetic($2.602B(26.02億美元))與 Juvederm 系列($993M(9.93億美元),−15.6%),受消費疲軟拖累。眼科($2.109B(21.09億美元),−5.9%)與其他重點產品($3.736B(37.36億美元),+2.4%——Creon $1.512B(15.12億美元)、Mavyret $1.317B(13.17億美元)、Linzess $907M(9.07億美元))構成其餘組合。

商業模式是在規模上跑專利懸崖跑步機:2025 年 GAAP 研發 $9.096B(90.96億美元),調整後研發投入 $13.8B(138億美元),另有逾 $5B(50億美元)的 2025 年業務開發(重度憂鬱症新型迷幻化合物、體內 CAR-T、siRNA 平台、肥胖症長效 amylin 類似物),在 Humira 衰退之際重建管線。2020 年收購 Allergan 把營收基礎多元化到醫美與眼科;ImmunoGen、Cerevel、Aliada、Capstan 等交易(以及 2026 年 6 月宣布的 $10.9B(109億美元)Apogee 收購)持續為腫瘤與神經科學管線供血。強勁的現金生成——2025 年營運現金流 $19.030B(190.3億美元)——支撐醫療健康業最長的股息連增紀錄之一(2025 年派息 $11.657B(116.57億美元))。

業務組合 — FY2025 淨營收(治療領域)

產品組合淨營收佔比同比重點產品
免疫學$30.406B(304.06億美元)49.7%+14.0%Skyrizi $17.56B(175.6億美元)· Rinvoq $8.30B(83億美元)· Humira $4.54B(45.4億美元)
神經科學$10.767B(107.67億美元)17.6%+19.6%Vraylar $3.62B(36.2億美元)· Botox Therapeutic $3.77B(37.7億美元)· Ubrelvy $1.27B(12.7億美元)· Qulipta $1.04B(10.4億美元)
腫瘤學$6.655B(66.55億美元)10.9%+1.5%Venclexta $2.79B(27.9億美元)· Imbruvica $2.87B(28.7億美元)· Elahere $0.69B(6.9億美元)· Epkinly $0.27B(2.7億美元)
醫美$4.860B(48.6億美元)7.9%−6.1%Botox Cosmetic $2.60B(26億美元)· Juvederm 系列 $0.99B(9.9億美元)
其他重點產品$3.736B(37.36億美元)6.1%+2.4%Creon $1.51B(15.1億美元)· Mavyret $1.32B(13.2億美元)· Linzess $0.91B(9.1億美元)
眼科$2.109B(21.09億美元)3.4%−5.9%Ozurdex $0.49B(4.9億美元)· Lumigan/Ganfort $0.41B(4.1億美元)
其他$2.627B(26.27億美元)4.3%n/m—
淨營收合計$61.160B(611.6億美元)100%+8.6%—
來源:艾伯維 FY2025 Form 10-K(會計年度截至2025年12月31日),重點產品營收。艾伯維按單一全球業務板塊(創新藥物與療法)申報;上表為管理層討論業務所用的治療領域口徑。佔比=產品組合營收 ÷ $61.160B(611.6億美元),四捨五入後合計可能不等於 100%。同比為申報口徑。

免疫學是後 Humira 時代的增長引擎。Skyrizi 與 Rinvoq 2025 年合計 $25.866B(258.66億美元),同比增加 $8.2B(82億美元);Humira 則從 2023 年的 $14.404B(144.04億美元)跌至 $4.540B(45.4億美元)。執行長 Robert Michael 指出,自失去專利保護以來美國 Humira 銷售侵蝕「接近 $16B(160億美元)」;公司目標 2027 年 Skyrizi/Rinvoq 合計銷售突破 $31B(310億美元)。

神經科學是增長最快的治療領域(+19.6%),以 Vraylar 與 Botox Therapeutic 為錨,偏頭痛雙藥 Ubrelvy/Qulipta(合計 $2.307B(23.07億美元))與帕金森新藥 Vyalev 接續。2024 年 $8.7B(87億美元)收購 Cerevel 加深神經科學管線;公司預期帕金森產品線(Vyalev 加 tavapadon)峰值銷售將超過 $5B(50億美元)。

腫瘤學處於換擋期:Venclexta(+8.1%)與 Elahere 抗體藥物複合體(+44.0%)增長,抵銷 Imbruvica(−14.3%,受 IRA 醫保議價與新一代 BTK 競爭衝擊)的下滑。2024 年 $10.1B(101億美元)收購 ImmunoGen 帶來 Elahere。

醫美與眼科是 Allergan 遺產——能產生現金但具週期性(醫美 −6.1%,消費疲軟)且面臨仿製藥壓力(眼科 −5.9%,主因 Restasis)。

歷史沿革

年份里程碑
20124月10日——AbbVie Inc. 於德拉瓦州註冊成立(FY2025 10-K 註1)
20131月1日——自 Abbott Laboratories 分拆完成;艾伯維成為獨立上市公司,承接 Humira(FY2025 10-K 註1)
2015以 $21B(210億美元)收購 Pharmacyclics——帶來首個腫瘤重磅藥 Imbruvica(公司 IR)
2019–20Allergan 收購宣布(2019年6月)並於 2020 年 5 月 8 日以 $63B(630億美元)完成——納入 Botox、Juvederm 系列與眼科產品線(公司 IR)
2023Humira 在美國首遇生物類似藥競爭(1月)——「製藥史上最大專利懸崖」(10-K 致股東信);Humira 美國銷售開始陡峭下滑
2024ImmunoGen 收購完成(2月,$10.1B(101億美元))——Elahere 抗體藥物複合體;Cerevel Therapeutics 收購完成(8月,$8.7B(87億美元))——神經科學管線;Aliada Therapeutics 收購(12月,$1.4B(14億美元))——阿茲海默抗體
20247月1日——Robert A. Michael 出任執行長;Vyalev 獲 FDA 批准用於晚期帕金森病(10月)
2025重要獲批:Rinvoq 治巨細胞動脈炎、Emrelis(telisotuzumab vedotin)治非鱗狀非小細胞肺癌、Epkinly 治二線濾泡性淋巴瘤(10-K 致股東信);收購 Capstan Therapeutics($2.1B(21億美元))——體內 CAR-T 平台;以 $906M(9.06億美元)首付款收購 Gilgamesh 重度憂鬱症迷幻化合物
20257月1日——Michael 出任董事長;Rick Gonzalez 榮休執行董事長(10-K 獨立董事信)
20266月22日(宣布)——收購 Apogee Therapeutics 最終協議,股權價值 $10.9B(109億美元),以長效生物製劑深化免疫學產品線;預計 2026 年第三季完成(2026 年第二季財報)

競爭地位

  • 規模——市值約 $504B(5,040億美元)(任務基線),醫療健康板塊市值第三、標普500第20大成分股(權重 0.71%);FY2025 淨營收 $61.160B(611.6億美元)創公司紀錄。
  • 免疫學引擎——Skyrizi($17.562B(175.62億美元),+49.9%)與 Rinvoq($8.304B(83.04億美元),+39.1%)2025 年合計 $25.866B(258.66億美元),佔總營收 42.3%,同比增加 $8.2B(82億美元);公司目標 2027 年合計突破 $31B(310億美元)(2025 年第四季電話會)。
  • 增長最快的治療領域——神經科學營收 $10.767B(107.67億美元),同比 +19.6%,由 Vraylar 與 Botox Therapeutic 領軍;帕金森產品線(Vyalev 加 tavapadon)預期峰值銷售超過 $5B(50億美元)。
  • Allergan 多元化——醫美($4.860B(48.6億美元))與眼科($2.109B(21.09億美元))提供傳統製藥週期之外的現金流,惟 2025 年雙雙下滑。
  • 股息機器——連續 54 年提高年度股息(2026年10月);2025 年派息 $11.657B(116.57億美元),對應自由現金流 $17.8B(178億美元);2025 年 10 月 31 日宣布季股息上調 5.5% 至 $1.73(1.73美元)(2026年2月17日支付)。
  • 研發與併購火力——2025 年 GAAP 研發 $9.096B(90.96億美元),調整後研發投入 $13.8B(138億美元);2025 年業務開發逾 $5B(50億美元)(Gilgamesh 迷幻化合物、體內 CAR-T、siRNA 平台、肥胖症 amylin 類似物);待完成的 $10.9B(109億美元)Apogee 交易將把免疫學延伸至長效生物製劑。
  • 競爭集合——免疫學與生物類似藥領域的 Johnson & Johnson、Eli Lilly、Novartis、Amgen;醫美領域的 Galderma、Merz;雙特異性抗體腫瘤領域的 Genmab(Epkinly 合作方);IRA 醫保議價已衝擊 Imbruvica。

財務快照 — FY2025

淨營收$61.160B(611.6億美元)(同比 +8.6% 申報口徑/+8.5% 固定匯率;FY2024 $56.334B(563.34億美元))
產品銷售成本$18.204B(182.04億美元)(同比 +7.7%)
毛利/毛利率$42.956B(429.56億美元)/ 70.2%(由申報數字計算)
銷售及管理費用$14.010B(140.1億美元)(同比 −5.0%)
研發(GAAP)$9.096B(90.96億美元)(同比 −28.9%;FY2024 含 Cerevel/ImmunoGen 大額費用)
收購中研發與里程碑$5.016B(50.16億美元)
營業利潤/營業利潤率$15.075B(150.75億美元)/ 24.6%(由申報數字計算)
調整後研發投入(非GAAP)$13.8B(138億美元)(10-K 致股東信)
淨利潤$4.233B(42.33億美元)(歸屬艾伯維 $4.226B(42.26億美元));淨利率 6.9%(計算值)
稀釋 EPS(GAAP)$2.36(2.36美元)(FY2024 為 $2.39(2.39美元))
調整後稀釋 EPS(非GAAP)$10.00(10美元)(同比 −1.2%;含每股 −$2.76(2.76美元)的收購中研發與里程碑費用)
營運現金流$19.030B(190.3億美元)
資本支出$1.214B(12.14億美元)
自由現金流$17.816B(178.16億美元)(營運現金流 − 資本支出;計算值)
總債務$64.997B(649.97億美元)(2025年12月31日長期債務與融資租賃)
現金及等價物$5.229B(52.29億美元)(2025年12月31日)
淨債務$59.768B(597.68億美元)(總債務 − 現金;計算值)
已付股息$11.657B(116.57億美元);季股息上調 5.5% 至 $1.73(1.73美元)(2025年10月31日;2026年2月17日支付;年化 $6.92(6.92美元))
最新一季(2026 年第二季,截至6月30日)淨營收 $16.990B(169.9億美元)(同比 +10.2%)· GAAP 稀釋 EPS $2.03(2.03美元)(同比 +290.4%)· 調整後稀釋 EPS $3.65(3.65美元)(同比 +22.9%;含每股 −$0.17(0.17美元)研發費用)· 調整後毛利率 84.7% · 調整後營業利潤率 48.3% · 2026 年全年指引:淨營收約 $67.6B(676億美元),調整後稀釋 EPS $13.87–14.07(13.87–14.07美元)(含 $0.14(0.14美元)Apogee 稀釋)
來源:艾伯維 FY2025 Form 10-K(2026年2月申報)與 2026 年第二季財報(2026年7月31日)。營業利潤($15.075B(150.75億美元))與淨利潤($4.233B(42.33億美元))之間的差距為 $10.842B(108.42億美元):$2.627B(26.27億美元)淨利息費用+$0.058B(0.58億美元)匯兌淨損失+$5.793B(57.93億美元)其他費用+$2.364B(23.64億美元)所得稅(FY2025 10-K)。毛利率、營業利潤率、淨利率與自由現金流由申報數字計算:毛利率($61.160B(611.6億美元)− $18.204B(182.04億美元))÷ $61.160B(611.6億美元)= 70.2%;營業利潤率 $15.075B(150.75億美元)÷ $61.160B(611.6億美元)= 24.6%;淨利率 $4.233B(42.33億美元)÷ $61.160B(611.6億美元)= 6.9%;自由現金流 $19.030B(190.3億美元)− $1.214B(12.14億美元)= $17.816B(178.16億美元);淨債務 $64.997B(649.97億美元)− $5.229B(52.29億美元)= $59.768B(597.68億美元)。

主要風險

  • 集中度——Skyrizi 與 Rinvoq 合計佔營收 42.3%(免疫學佔 49.7%);任一產品出現安全性訊號、報銷挫折或競爭失利都是公司級事件。
  • Humira 長尾——2025 年仍在侵蝕(−49.5% 至 $4.540B(45.4億美元)),生物類似藥競爭與獨家生物類似藥合約擴散;預期准入將進一步下降。
  • Imbruvica 壓力——IRA 醫保議價加新一代 BTK 競爭,FY2025 營收 −14.3%,2026 年第二季 −29.4%。
  • 槓桿——2025 年底淨債務 $59.8B(598億美元)(總債務 $65.0B(650億美元));$10.9B(109億美元)Apogee 收購增加債務,公司承諾交割後 2–3 年內回到約 2 倍淨槓桿,制約回購與併購彈性。
  • 管線與併購依賴——2025 年收購中研發與里程碑 $5.016B(50.16億美元),或有對價公允價值變動 $6.495B(64.95億美元),GAAP 盈利持續波動,增長依賴外部科學。
  • 定價與週期——美國支付方與 IRA 定價壓力貫穿產品線;醫美(2025 年 −6.1%)暴露於可選消費週期。

對標普500的重要性

艾伯維是指數第 20 大成分股,權重 0.71%(任務基線)——ABBV 單獨波動 1%,標普500 大約動 0.7 個基點——也是醫療健康板塊市值第三名。它是指數中最純的大型生物科技風向標(GICS 子行業為生物科技,按任務基線),與 Johnson & Johnson、Eli Lilly、UnitedHealth 同為 XLV 的錨定權重之一。

對市場結構觀察者而言,ABBV 是三個主題的板塊讀數:史上最大專利懸崖之後的生物類似藥侵蝕速度(Humira)、新一代免疫生物製劑的定價權(Skyrizi/Rinvoq),以及 IRA 醫保藥品議價的實際衝擊(Imbruvica)。連續 54 年提高年度股息,它也是醫療健康板塊的收益錨——2025 年 $11.657B(116.57億美元)股息被 $17.8B(178億美元)自由現金流舒適覆蓋。

來源與方法

財務、產品組合、員工、債務艾伯維 FY2025 Form 10-K(2026年2月申報;會計年度截至2025年12月31日;合併報表、註1、板塊披露)
最新一季(2026 年第二季)艾伯維 2026 年第二季財報(2026年7月31日;季度截至2026年6月30日)
指數權重與排名任務基線(標普500 #20 · 0.71%)
市值與板塊排名任務基線($504B(5,040億美元)· 醫療健康 #3)
歷史10-K 註1(註冊成立、Abbott 分拆);10-K 致股東信與獨立董事信(領導層、Humira 專利懸崖、2025 年業務開發與獲批);艾伯維 IR 新聞稿(Pharmacyclics、Allergan、ImmunoGen、Cerevel、Aliada、Capstan、Apogee)
股息艾伯維 IR(2025年10月31日股息宣告);股息歷史(stockanalysis.com,2026年10月)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。

10年股價K線圖(月K)

AbbVie

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · ABBV
Data as of Oct 21, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Intel Corporation (INTC) — XLK Information Technology · S&P 500 Profile |英特爾公司介紹Next · Mastercard Incorporated (MA) — XLF Financials · S&P 500 Profile |萬事達公司介紹

Entered 2026-10-24 10:15 · updated 2026-11-14 22:50 · rev 11